Homepage

Clinical Guidelines for Antidepressant Dosage Must Reflect the Evidence

New analysis shows the lower range of the licensed dose of the most commonly used second-generation antidepressants achieves the optimal balance between efficacy, tolerability and acceptability in the acute treatment of adults with major depression.

Experts call for new kind of registry for deployment of psychedelics as medicines

The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.

Self-harm in Children and Adolescents: A Major Health and Social Problem of our Time

In the Jack Tizard Memorial Lecture during the Association for Child and Mental Health National Conference at the Royal College of Physicians, Professor Keith Hawton, highlighted the very worrying recent increases in rates of suicide in England in older adolescents and the big rise in self-harm in young teenage females.

Close Monitoring Essential to Ensure Safety of Ketamine for Depression

Patients, carers and advocates say better evidence is needed on the safety of ketamine for depression after long-term use, and that those prescribed it must be closely monitored.

Oxford Short Course in Experimental Medicine for Mental Health - OxCEMM

This new course ran for the first time in January 2019, with an engaging and thought-provoking programme of talks, tours of facilities and group discussions. Feedback from participants was uniformly excellent. Applications for the January 2020 course open on 15th August 2019.